Corcept Therapeutics (FRA:HTD) Short Ratio


FRA:HTD Corcept Therapeutics Inc FRA:HTD
80 GF Score
Price €77.44
GF Value €53.55
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Corcept Therapeutics Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:HTD
80GF Score
Corcept Therapeutics Inc FRA:HTD
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Corcept Therapeutics (FRA:HTD) Overvalued in 2026?

Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued. The current stock price of €77.44 is trading 44.6% above its estimated GF Value™ of €53.55. GuruFocus considers Corcept Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:HTD:

  • Short Ratio:
  • GF Value™: €53.55 vs. price of €77.44 (44.6% above fair value)
  • GF Score™: 80/100 with 8 warning signs

No single metric tells the full story. See the FRA:HTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Corcept Therapeutics Business Description

Other Exchanges CORT:USA1CORT:Italy0I3Q:UK
Address 101 Redwood Shores Parkway, Redwood City, CA, USA, 94065
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
80GF Score

Get the complete analysis for FRA:HTD

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€77.44
Price
€53.55
GF Value